AstraZeneca (AZN)
Salud / Farmacéutica
AstraZeneca is a global biopharmaceutical company with four growth therapy areas —Oncology, Cardiovascular-Renal-Metabolic, Respiratory & Immunology, and Rare Disease— protected by a staggered patent portfolio with extensions through 2041 and a pipeline of more than a hundred programs in Phases I to III. Revenue grew at a double-digit rate in two of the last three fiscal years, and the company is pursuing its own ambition of USD 80 billion in revenue by 2030. At $169 the stock trades It trades close to intrinsic value, far from the required margin of safety., with Fairly valued and an estimated total return of +5% annually over five years, appreciation plus a growing dividend.
- Price
- $169.22
- Intrinsic value (5y, base)
- $189
- Total annual return (5y)
- 5.1%
- Status (nominal)
- Fairly valued
- Margin of safety
- +3%
The essentials
- The company's own ambition of USD 80 billion in revenue by 2030, consistent with the model's base path (implying ~6.4% CAGR from FY2025 revenue of US$58,739M).
- Return on invested capital of 15%, above the 10% bar, backed by leading franchises in oncology and rare disease.
- Semi-annual dividend with 5.4% recent annual growth, funded by operating cash flow of US$14,575M in FY2025.
Intrinsic value — two valuation methods
Total return at 5 years: 5.1%/year = 2.2% appreciation + 2.8% dividend. The target price ($189) is ex-dividend; the $25 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $297 · Multiples $174) exceeds the market price ($169).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $169 trades ~2.6% below its value discounted to today (~$174); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($189) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$111.
Thesis
The business
A globally diversified biopharmaceutical company across four growth therapy areas, with a wide moat from staggered patents through 2041 and a pipeline of more than a hundred programs. Business quality is high —return on invested capital of 15.0% against the 10% bar— though with real exposure to patent expiration in its historically largest franchise (Farxiga) and to the binary risk of clinical development.
The valuation
Valued on P/E over adjusted post-interest earnings (owner earnings), with an exit multiple derived from the pharmaceutical archetype band (14x-22x) based on terminal growth, moat width, and return on capital. The revenue path starts from the company's reconfirmed FY2026 guidance and converges with its own USD 80 billion ambition for 2030, yielding a five-year value of $189 per share.
The margin of safety
Against a market price of $169, the stock It trades close to intrinsic value, far from the required margin of safety.. The estimated total return over five years —appreciation plus the growing semi-annual dividend (current yield and its 5.4% annual growth)— is +5% annually, resulting in a verdict of Fairly valued.
What to watch
The central disconfirmer of the thesis is whether the pipeline keeps delivering at the pace needed to offset CVRM erosion from Farxiga's U.S. patent expiration. The CARDIO-TTRansform and EMERALD-2 failures in H1 2026 are a reminder that this replacement is not guaranteed; if the more than twenty high-value readouts expected over the next 18 months disappoint systematically, the growth path and the exit multiple would prove overstated.
Educational / informational. Does not constitute investment advice.